Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs MBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBX Captures Overall Composite Edge (44.9 HOLD vs 55.8 HOLD), While XOMA Leads 3–1 on Growth & Valuation Pillars

MBX Overall Winner 6-Pillar Tally: XOMA 3 – 1 MBX (2 Tie) Matrix Metrics: XOMA 7 – 3 MBX

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (44.9/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale), while XOMA wins 3–1 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus MBX at $53.69 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.9% operating margin) and revenue trajectory (+0.0% vs. -22.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs MBX
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
MBX NASDAQ Head-to-Head Winner
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.69
-4.02% 1D
Market Cap $2.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.58β · 65% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $53.41 · SMA50: $55.62

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 1 MBX)

Columns: Metric · XOMA · MBX
1. Valuation Multiples XOMA
Forward P/E 21.5x N/M
Trailing P/E 28.2x N/M
PEG Ratio N/M N/M
EV / Revenue 16.1x N/M
2. Growth & Scale MBX
Revenue Growth (YoY) -22.6% +0.0%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M N/A
Market Cap $781.8M $2.7B
3. Profitability & Quality XOMA
Gross Margin 99.0% N/A
Operating Margin -3.9% 0.0%
Net Profit Margin 69.6% 0.0%
Return on Equity (ROE) 34.2% -33.7%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA N/A
Cash Flow Margin 17.1% EBITDA Mgn N/A
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $9.53 Book/Sh · -33.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 101.5% (100th %ile) 64.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (7) vs MBX (3)
Institutional Metric XOMA MBX Criterion Row Edge
Market Capitalization
Scale
$781.8M $2.7B Larger Scale MBX
Trailing P/E Ratio
Valuation
28.2x N/M Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x N/M Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-22.6% +0.0% Higher Growth MBX
Operating Margin (TTM)
Profitability
-3.9% 0.0% Higher Margin MBX
Net Profit Margin
Profitability
69.6% 0.0% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -33.7% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 62% ($23–$73) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.58β · 65% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) N/A ($9.53 Book/Sh · -33.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBX +97.55 pp
XOMA: -3.81% · MBX: +93.74%
3M Horizon MBX +84.34 pp
XOMA: +9.34% · MBX: +93.68%
6M Horizon MBX +61.18 pp
XOMA: +34.26% · MBX: +95.44%
1Y Horizon MBX +124.84 pp
XOMA: +24.6% · MBX: +149.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs MBX. Trailing 12-month operating profitability (XOMA -3.9% vs MBX 0.0%) and valuation multiples (XOMA 21.5x vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
MBX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-33.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 64.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs MBX Key Questions & Quantitative Answers

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (44.9/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale), while XOMA wins 3–1 across the 6-pillar growth and valuation breakdown. XOMA trades at $40.17 (21.5x Forward P/E, -3.9% operating margin) versus MBX at $53.69 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.9% operating margin) and revenue trajectory (+0.0% vs. -22.6% YoY).

MBX leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with MBX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus N/A for MBX. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBX.

XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas MBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus MBX (-33.7% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, MBX carries 64.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.